Cancer drugs
Jump to navigation
Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
This article covers cancer drugs from a pathology perspective.
Drugs in a table
Non-proprietary name | Trade name | Cost | Indication | Notes |
---|---|---|---|---|
cetuximab | Erbitux | 5267 Euros/month[1] | stomach cancer, head & neck cancer | notes? |
trastuzumab | Herceptin | 3345 Euros/month[1] | breast cancer, stomach cancer | notes? |
gefitinib | Iressa | 3496 Euros/month[1] | lung cancer | EGFR inhibitor - like erlotinib |
panitumumab | Vectibix | 3537 Euros/month[1] | indication ??? | notes? |
fulvestrant | Faslodex | 719 Euros/month[1] | breast cancer | selective estrogen receptor down-regulator (SERD) |
letrozole | Femara | 4189 Euros/month[1] | indication ??? | non-steroidal aromatase inhibitor |
imatinib | Gleevec/Glivec | 4189 Euros/month[1] | ALL, CML | tyrosine kinase inhibitor |
dasatinib | Sprycel | 7513 Euros/month[1] | ALL, CML | tyrosine kinase inhibitor |
nilotinib | Tasigna | 5685 Euros/month[1] | CML | tyrosine kinase inhibitor |
lapatinib | Tyverb | 3441 Euros/month[1] | breast cancer | tyrosine kinase inhibitor / HER2 growth receptor pathway blockade |